1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 11
1.3 PEST Analysis 12
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 13
2.3 Research Methodology 14
2.4 Report Assumptions 14
3 Market Snapshot 16
3.1 Total Addressable Market (TAM) 16
3.2 Segmented Addressable Market (SAM) 16
3.3 Related Markets 17
3.3.1 mHealth Market 17
3.3.2 Healthcare Analytics Market 18
4 Market Outlook 18
4.1 Overview 18
4.2 Regulatory Bodies and Standards 19
4.3 Government Spending and Initiatives 19
4.4 Porter 5 (Five) Forces 21
5 Market Characteristics 22
5.1 Evolution 22
5.2 Ecosystem 25
5.2.1 Regulatory Process 25
5.2.2 Clinical Trials 25
5.2.3 Pricing and Reimbursement 26
5.3 Market Segmentation 28
5.4 Market Dynamics 28
5.4.1 Drivers 29
5.4.1.1 Emergence of nanorobotics 29
5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 29
5.4.1.3 Reasonable investments in R&D 30
5.4.1.4 Increased support from governments 30
5.4.2 Restraints 31
5.4.2.1 Long approval process and stringent regulations 31
5.4.2.2 Problems regarding nanoscale manufacturing 31
5.4.2.3 Risks related to nanomedicines 31
5.4.2.4 Undefined regulatory standards 31
5.4.3 Opportunities 32
5.4.3.1 Aging population with chronic care needs 32
5.4.3.2 Population and income growth in emerging countries 32
5.4.4 DRO - Impact Analysis 33
6 Trends' Roadmap and Projects 34
6.1 Market Trends and Impact 34
6.2 Technology Roadmap 35
7 Types: Market Size and Analysis 36
7.1 Overview 36
7.2 Global Nanomedicine Market in Oncology Segment 37
7.3 Global Nanomedicine Market in Cardiovascular Segment 38
7.4 Global Nanomedicine Market in Neurology Segment 39
7.5 Global Nanomedicine Market in Anti-inflammatory Segment 39
7.6 Global Nanomedicine Market in Anti-infective Segment 40
7.7 Global Nanomedicine Market in Other Therapeutic Areas 41
8 Trending Nanomedicines 42
8.1 Overview 42
8.2 Abraxane 43
8.3 Alimta 43
8.4 Eligard 44
8.5 Copaxone 44
8.6 Rapamune 44
8.7 Neulasta 45
8.8 Cimzia 45
8.9 AmBisome 46
8.10 Mircera 46
8.11 Pegasys 46
8.12 Emend 47
8.13 Renagel 47
8.14 Ritalin 47
9 Regions: Market Size and Analysis 48
9.1 Overview 48
9.1.1 Global Nanomedicine Market by Geographical Segmentation 49
9.2 Key Leading Countries 49
9.2.1 US 49
9.2.2 Germany 50
9.2.3 Japan 50
10 Vendor Scenario 50
11 Vendor Profiles 53
11.1 Merck & Co. Inc. 53
11.1.1 Overview 53
11.1.2 Business Unit 55
11.1.3 Geographic Revenue 57
11.1.4 Recent Developments 58
11.1.5 SWOT Analysis 58
11.1.6 Business Strategies 60
11.2 Hoffmann-La Roche Ltd. 60
11.2.1 Overview 60
11.2.2 Business Unit 61
11.2.3 Geographic Revenue 63
11.2.4 Recent Developments 63
11.2.5 SWOT Analysis 65
11.2.6 Business Strategies 66
11.3 Gilead Sciences 66
11.3.1 Overview 66
11.3.2 Business Unit 68
11.3.3 Geographic Revenue 70
11.3.4 Recent Developments 70
11.3.5 SWOT Analysis 71
11.3.6 Business strategies 71
11.4 Novartis AG 71
11.4.1 Overview 71
11.4.2 Business Unit 72
11.4.3 Geographic Revenue 74
11.4.4 Recent Developments 74
11.4.5 SWOT Analysis 76
11.4.6 Business Strategies 76
11.5 Amgen Inc. 77
11.5.1 Overview 77
11.5.2 Business Unit 78
11.5.3 Geographic Revenue 79
11.5.4 Recent Developments 79
11.5.5 SWOT Analysis 80
11.5.6 Business Strategies 81
12 Global Generalist 82
12.1 Pfizer Inc. 82
12.1.1 Overview 82
12.1.2 Recent Developments 82
12.1.3 Pfizer in 2015 83
12.2 Eli Lilly and Company 84
12.2.1 Overview 84
12.2.2 Recent Developments 85
12.2.3 Eli Lilly and Company in 2015 85
12.3 Sanofi 86
12.3.1 Overview 86
12.3.2 Recent Developments 86
12.3.3 Sanofi in 2015 87
13 Companies to Watch for 87
13.1 Nanobiotix SA 87
13.1.1 Overview 87
13.1.2 Offering 88
13.1.3 Recent Developments 88
13.2 UCB SA 89
13.2.1 Overview 89
13.2.2 Offering 89
13.2.3 Recent Developments 90
14 Market Landscape 91
14.1 Market Landscape 91
14.1.1 Mergers & Acquisitions (M&A) 91
Annexure 93
? Abbreviations 93